U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older…
Browsing Tag
subcutaneous administration
1 post